Clinical Development Times for Biosimilars in the United States.

[1]  A. Kesselheim,et al.  Why Are Biosimilars Not Living up to Their Promise in the US? , 2019, AMA journal of ethics.

[2]  Jonathan J. Darrow,et al.  The US Biosimilar Market: Stunted Growth and Possible Reforms , 2018, Clinical pharmacology and therapeutics.

[3]  V. Azevedo,et al.  The biosimilars journey: current status and ongoing challenges , 2018, Drugs in context.

[4]  J. Ross,et al.  Obstacles to the Adoption of Biosimilars for Chronic Diseases. , 2017, JAMA.

[5]  Michael A. Carrier,et al.  Biologics: The New Antitrust Frontier , 2017 .

[6]  L. Martin,et al.  Trial watch: Clinical trial cycle times continue to increase despite industry efforts , 2017, Nature Reviews Drug Discovery.

[7]  A. Kesselheim,et al.  Progress and Hurdles for Follow-on Biologics. , 2015, The New England journal of medicine.

[8]  W. Price,et al.  Are trade secrets delaying biosimilars? , 2015, Science.

[9]  Joseph A DiMasi,et al.  Economics of new oncology drug development. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.